Article
Immunology
Jan-Lukas Forde, Lars Herfindal, Kjell-Morten Myhr, Oivind Torkildsen, Tom Eirik Mollnes, Silje Skrede
Summary: This study compared the complement activation of ocrelizumab, ofatumumab, and rituximab. The results showed that ofatumumab, ocrelizumab, and infliximab could trigger complement activation, while rituximab and adalimumab did not have this potential. These findings are important for understanding the differences in anti-CD20 mAbs used in the treatment of multiple sclerosis.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Clinical Neurology
David Baker, Amy MacDougall, Angray S. Kang, Klaus Schmierer, Gavin Giovannoni, Ruth Dobson
Summary: Ocrelizumab differs from other treatments in its inhibitory effect on seroconversion, potentially resulting in delayed repletion of B cells within 3 months. Controlled studies are necessary to explore whether delaying the dosing interval by 3-6 months post-vaccination may increase the potential for seroconversion.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2022)
Article
Clinical Neurology
Alyssa A. Toorop, Zoe Y. G. van Lierop, Eva E. M. Strijbis, Charlotte E. Teunissen, Axel Petzold, Mike P. Wattjes, Frederik Barkhof, Brigit A. de Jong, Zoe L. E. van Kempen, Joep Killestein
Summary: Two patients with relapsing-remitting MS developed carryover PML after switching from natalizumab to ocrelizumab. Despite mild immune reconstitution inflammatory syndrome (IRIS) and increasing NfL levels, PML-IRIS lesions stabilized after treatment and both patients continued therapy with ocrelizumab.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
(2021)
Article
Immunology
Julia Baguna Torres, Jay Roodselaar, Megan Sealey, Marina Ziehn, Marc Bigaud, Rainer Kneuer, David Leppert, Gisbert Weckbecker, Bart Cornelissen, Daniel C. Anthony
Summary: This study investigated the distribution and efficacy of ofatumumab and ocrelizumab in huCD20 transgenic mice, revealing differences in tissue distribution patterns between subcutaneous and intravenous administration, with the possibility of more direct access to lymph nodes through the lymphatic system with subcutaneous administration. Additionally, preliminary findings suggest that ofatumumab may be more effective than ocrelizumab at controlling MS-like pathology in the brain.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Health Care Sciences & Services
Mansour A. Alharbi, Fahad Aldosari, Ahmed Hasan Althobaiti, Faris M. Abdullah, Salman Aljarallah, Nuha M. Alkhawajah, Miteb Alanazi, Yazed AlRuthia
Summary: This study aimed to compare the direct medical cost and consequences of rituximab and natalizumab in managing RRMS in Saudi Arabia. Findings showed that rituximab appears to be more effective and less costly than natalizumab, while ocrelizumab does not seem to slow disease progression in patients previously treated with natalizumab.
BMC HEALTH SERVICES RESEARCH
(2023)
Article
Clinical Neurology
Stephen L. Hauser, Ludwig Kappos, Xavier Montalban, Licinio Craveiro, Cathy Chognot, Richard Hughes, Harold Koendgen, Noemi Pasquarelli, Ashish Pradhan, Kalpesh Prajapati, Jerry S. Wolinsky
Summary: This study reports the safety of ocrelizumab treatment for up to 7 years in patients with multiple sclerosis, showing a consistent and manageable safety profile without emerging safety concerns. The rates of the most common serious adverse events, including serious infections and malignancies, were consistent with epidemiologic data ranges. Additionally, long-term, continuous treatment with ocrelizumab was associated with a favorable safety profile in a heterogeneous multiple sclerosis population.
Article
Hematology
Mathias J. Rummel, Ann Janssens, David MacDonald, Mary-Margaret Keating, Jan M. Zaucha, Jaclyn Davis, Janet Lasher, Chaitali Babanrao Pisal, Miguel Izquierdo, Jonathan W. Friedberg
Summary: This study compared the efficacy of ofatumumab and bendamustine combination therapy with bendamustine monotherapy in rituximab-refractory iNHL patients, showing no significant improvement in PFS and OS with the combination therapy.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Clinical Neurology
Cavit Boz, Serkan Ozakbas, Murat Terzi, Rana Karabudak, Serhan Sevim, Recai Turkoglu, Aysun Soysal, Belgin Petek Balci, Husnu Efendi, Omer Faruk Turan, Nur Yuceyar, Mehmet Fatih Yetkin, Serap Zengin Karahan, Meltem Demirkiran, Sibel Guler, Kadriye Agan, Nefati Kiylioglu, Cavid Baba, Asli Tuncer, Mesrure Koseoglu
Summary: This study compared the efficacy of three drugs (fingolimod, natalizumab, and ocrelizumab) in reducing disease activity in RRMS. The results showed that natalizumab and ocrelizumab had similar effects on relapse control, and both were better than fingolimod. The three therapies had similar effects on disability outcomes.
NEUROLOGICAL SCIENCES
(2023)
Article
Clinical Neurology
Albert Munoz-Vendrell, Pablo Arroyo-Pereiro, Isabel Leon, Laura Bau, Elisabet Matas, Antonio Martinez-Yelamos, Sergio Martinez-Yelamos, Lucia Romero-Pinel
Summary: JC virus (JCV) serology can be used as a natural experiment to compare treatment arms, and switching to ocrelizumab (OCR) versus continuing natalizumab (NTZ) treatment led to similar disease activity outcomes.
JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Stephen L. Hauser, Amit Bar-Or, Martin S. Weber, Heidemarie Kletzl, Andreas Guenther, Marianna Manfrini, Fabian Model, Francois Mercier, Claire Petry, Qing Wing, Harold Koendgen, Terence Smith, Ludwig Kappos
Summary: Ocrelizumab demonstrated improvement in clinical and MRI measures of disease activity and progression in multiple sclerosis patients. Higher serum levels of ocrelizumab were associated with more complete B-cell depletion and a greater delay in disability progression. The exposure-response relationship analysis showed that higher ocrelizumab exposure led to lower risk of disability progression.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
(2023)
Article
Clinical Neurology
Carmen Alcala, Carlos Quintanilla-Bordas, Francisco Gascon, Angel Perez Sempere, Laura Navarro, Maria Carcelen-Gadea, Lamberto Landete, Javier Mallada, Emmanuel Canizares, Antonio Belenguer, Sara Carratala, Jose Andres Dominguez, Francisco Carlos Perez-Miralles, Sara Gil-Perotin, Raquel Gasque, Laura Cubas, Jessica Castillo, Bonaventura Casanova
Summary: This study compared the effectiveness of rituximab and ocrelizumab in patients with primary progressive multiple sclerosis (pwPPMS) under real-life conditions. The findings showed no differences in time to confirmed disability progression between the two treatments. However, further clinical trials are needed to confirm these results.
JOURNAL OF NEUROLOGY
(2022)
Article
Clinical Neurology
Nicola Capasso, Agostino Nozzolillo, Giulia Scalia, Roberta Lanzillo, Antonio Carotenuto, Marcello De Angelis, Martina Petruzzo, Francesco Sacca, Cinzia Valeria Russo, Vincenzo Brescia Morra, Marcello Moccia
Summary: Both rituximab and ocrelizumab similarly decrease B-cell levels in peripheral blood of multiple sclerosis patients, but ocrelizumab shows a more pronounced reduction in CD4 and CD8 T lymphocytes. The two antibodies have comparable effects on reducing lymphocyte count, and the broader immunomodulatory effect of ocrelizumab needs to be confirmed and correlated with long-term clinical efficacy.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2021)
Article
Clinical Neurology
Marco Puthenparampil, Marta Gaggiola, Alessandro Miscioscia, Valentina Annamaria Mauceri, Federica De Napoli, Giovanni Zanotelli, Mariagiulia Anglani, Margherita Nosadini, Stefano Sartori, Paola Perini, Francesca Rinaldi, Paolo Gallo
Summary: This study evaluated the efficacy and safety of alemtuzumab (ALZ) in pediatric-onset multiple sclerosis (POMS) and adult-onset multiple sclerosis (AOMS) patients undergoing treatment switch. The results showed that ALZ was more effective in AOMS patients compared to POMS patients after switching from natalizumab (NTZ). However, these findings may underestimate the effectiveness of ALZ in POMS patients.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
(2023)
Article
Clinical Neurology
Marina Rode von Essen, Rikke Holm Hansen, Camilla Hojgaard, Cecilie Ammitzboll, Heinz Wiendl, Finn Sellebjerg
Summary: This study shows that ofatumumab treatment is effective in controlling effector T cells and reducing T cell autoreactivity in patients with RRMS. It also demonstrates that ofatumumab reduces the level of peripheral CD20(+) T cells and decreases the CNS-migratory capacity of T cells.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
(2022)
Article
Clinical Neurology
Jose Fernandez-Velasco, Jens Kuhle, Enric Monreal, Virginia Meca-Lallana, Jose Meca-Lallana, Guillermo Izquierdo, Francisco Gascon-Gimenez, Susana Sainz de la Maza, Paulette E. Walo-Delgado, Aleksandra Maceski, Eulalia Rodriguez-Martin, Ernesto Roldan, Noelia Villarrubia, Albert Saiz, Yolanda Blanco, Pedro Sanchez, Ester Carreon-Guarnizo, Yolanda Aladro, Luis Brieva, Cristina Iniguez, Ines Gonzalez-Suarez, Luis A. Rodriguez de Antonio, Jaime Masjuan, Lucienne Costa-Frossard, Luisa M. Villar
Summary: Ocrelizumab induced changes in immune cell distribution in patients with primary progressive MS, reducing inflammatory cells and leading to a decrease in sNfL levels.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
(2021)
Article
Immunology
S. Hahn, G. Trendelenburg, M. Scharf, Y. Denno, S. Brakopp, B. Teegen, C. Probst, K. P. Wandinger, M. Buttmann, A. Haarmann, F. Szabados, M. vom Dahl, T. Kuempfel, P. Eichhorn, H. Gold, F. Paul, S. Jarius, N. Melzer, W. Stoecker, L. Komorowski
JOURNAL OF NEUROINFLAMMATION
(2017)
Article
Neurosciences
Isabelle Wirsching, Mathias Buttmann, Thorsten Odorfer, Jens Volkmann, Joseph Classen, Daniel Zeller
EUROPEAN JOURNAL OF NEUROSCIENCE
(2018)
Article
Immunology
A. Haarmann, L. Haehnel, M. K. Schuhmann, M. Buttmann
JOURNAL OF NEUROIMMUNOLOGY
(2018)
Article
Immunology
Christine Silwedel, Christian P. Speer, Axel Haarmann, Markus Fehrholz, Heike Claus, Mathias Buttmann, Kirsten Glaser
JOURNAL OF NEUROINFLAMMATION
(2018)
Editorial Material
Clinical Neurology
M. Buttmann
EUROPEAN JOURNAL OF NEUROLOGY
(2018)
Article
Biochemistry & Molecular Biology
Axel Haarmann, Michael K. Schuhmann, Christine Silwedel, Camelia-Maria Monoranu, Guido Stoll, Mathias Buttmann
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2019)
Article
Clinical Neurology
Marius Ringelstein, Jens Harmel, Hanna Zimmermann, Alexander U. Brandt, Friedemann Paul, Axel Haarmann, Mathias Buttmann, Martin W. Huemmert, Corinna Trebst, Christoph Schroeder, Ilya Ayzenberg, Ingo Kleiter, Kerstin Hellwig, Joachim Havla, Tania Kuempfel, Sven Jarius, Brigitte Wildemann, Paulus Rommer, Martin S. Weber, Hannah Pellkofer, Luise Roepke, Christian Geis, Nele Retzlaff, Uwe Zettl, Michael Deppe, Luisa Klotz, Kim Young, Jan-Patrick Stellmann, Matthias Kaste, Pawel Kermer, Wael Marouf, Florian Lauda, Hayrettin Tumani, Jonas Graf, Alexander Klistorner, Hans-Peter Hartung, Orhan Aktas, Philipp Albrecht
Article
Cell Biology
Paloma Gomez-Fernandez, Aitzkoa Lopez de Lapuente Portilla, Ianire Astobiza, Jorge Mena, Andoni Urtasun, Vivian Altmann, Fuencisla Matesanz, David Otaegui, Elena Urcelay, Alfredo Antiguedad, Sunny Malhotra, Xavier Montalban, Tamara Castillo-Trivino, Laura Espino-Paisan, Orhan Aktas, Mathias Buttmann, Andrew Chan, Bertrand Fontaine, Pierre-Antoine Gourraud, Michael Hecker, Sabine Hoffjan, Christian Kubisch, Tania Kuempfel, Felix Luessi, Uwe K. Zettl, Frauke Zipp, Iraide Alloza, Manuel Comabella, Christina M. Lill, Koen Vandenbroeck
Article
Immunology
Sven Jarius, Hannah Pellkofer, Nadja Siebert, Mirjam Korporal-Kuhnke, Martin W. Huemmert, Marius Ringelstein, Paulus S. Rommer, Ilya Ayzenberg, Klemens Ruprecht, Luisa Klotz, Nasrin Asgari, Tobias Zrzavy, Romana Hoeftberger, Rafik Tobia, Mathias Buttmann, Kai Fechner, Kathrin Schanda, Martin Weber, Susanna Asseyer, Juergen Haas, Christian Lechner, Ingo Kleiter, Orhan Aktas, Corinna Trebst, Kevin Rostasy, Markus Reindl, Tania Kuempfel, Friedemann Paul, Brigitte Wildemann
JOURNAL OF NEUROINFLAMMATION
(2020)
Letter
Clinical Neurology
Marius Ringelstein, Jens Harmel, Hanna Zimmermann, Alexander U. Brandt, Friedemann Paul, Axel Haarmann, Mathias Buttmann, Martin W. Huemmert, Corinna Trebst, Christoph Schroeder, Ilya Ayzenberg, Ingo Kleiter, Kerstin Hellwig, Joachim Havla, Tania Kuempfel, Sven Jarius, Brigitte Wildemann, Paulus Rommer, Martin Weber, Hannah Pellkofer, Luise Roepke, Christian Geis, Nele Retzlaff, Uwe Zettl, Michael Deppe, Luisa Klotz, Kim Young, Jan-Patrick Stellmann, Matthias Kaste, Pawel Kermer, Wael Marouf, Florian Lauda, Hayrettin Tumani, Jonas Graf, Sasha Klistorner, Hans-Peter Hartung, Orhan Aktas, Philipp Albrecht
Meeting Abstract
Clinical Neurology
S. Meuth, M. Buttmann, M. Weber, P. Dirks, J. Eggebrecht, N. Joschko, J. Leemhuis, M. Martinec, E. Muros-Le Rouzic, K. A. Zalocusky, T. Ziemssen
MULTIPLE SCLEROSIS JOURNAL
(2020)
Meeting Abstract
Clinical Neurology
M. Buttmann, S. Meuth, M. Weber, P. Dirks, J. Eggebrecht, S. Hieke-Schulz, J. Leemhuis, T. Ziemssen
MULTIPLE SCLEROSIS JOURNAL
(2020)
Meeting Abstract
Clinical Neurology
M. Buttmann, S. Meuth, M. Weber, P. Dirks, J. Eggebrecht, S. Hieke-Schulz, J. Leemhuis, T. Ziemssen
MULTIPLE SCLEROSIS JOURNAL
(2020)
Meeting Abstract
Clinical Neurology
M. Ringelstein, J. Harmel, H. Zimmermann, A. U. Brandt, F. Paul, A. Haarmann, M. Buttmann, M. W. Huemmert, C. Trebst, C. Schroeder, I. Ayzenberg, I. Kleiter, K. Hellwig, J. Havla, T. Kuempfel, S. Jarius, B. Wildemann, P. Rommer, M. S. Weber, H. Pellkofer, L. Roepke, C. Geis, N. Retzlaff, U. Zettl, M. Deppe, L. Klotz, K. Young, J. -P. Stellmann, M. Kaste, P. Kermer, W. Marouf, F. Lauda, H. Tumani, J. Graf, H. -P. Hartung, O. Aktas, P. Albrecht
MULTIPLE SCLEROSIS JOURNAL
(2018)
Meeting Abstract
Immunology
F. Dennstaedt, C. Hollmann, T. Wiese, S. Stonawski, C. Wurst, M. Buttmann, A. Menke, J. Schneider-Schaulies, N. Beyersdorf
EUROPEAN JOURNAL OF IMMUNOLOGY
(2017)